Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of IIIB/IV stage NSCLC patients who are not suitable for surgery or radiotherapy * ECOG performance status points (PS) is 0-2 * Liver function: A (mild hepatic dysfunction): A1) total bilirubin within normal limit (ULN), while AST\> ULN; A2) total bilirubin within1.0-1 .5 × ULN; B (moderate hepatic dysfunction): total bilirubin within1.5-3 .0 × ULN * No malabsorption or other gastrointestinal disorders effecting drug absorption * Life expectancy: more than 12 weeks. Exclusion Criteria: * Previous usage of HER/EGFR inhibitors or other target molecule drugs ( small molecule drugs or monoclonal antibody therapy ) * Patients requires liver shunt , stent placement, or radiotherapy when 2 weeks before the start of the study or research process . * Patients with active hepatitis and cirrhosis.